Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK supports smoking cessation campaign

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline partners with the American Legacy Foundation to provide 125,000 free Nicorette gum starter packs to participants in the EX smoking cessation program. "Study after study shows that when smokers have access to a broad range of tools to help them quit, they are more successful in the long term," said Karen Scollick, VP of behavioral science for GSK Consumer Healthcare, in a Jan. 20 release. The EX campaign, backed by the National Alliance for Tobacco Cessation, offers personalized quit-plans and other resources at 1www.BecomeAnEX.org. GSK actively encourages greater use of nicotine replacement therapies, including asking FDA to update NRT indications to allow for longer duration of use (2"The Tan Sheet" Dec. 7, 2009)

You may also be interested in...



GSK Asks FDA To Mull Expansion Of NRT Indications

GlaxoSmithKline's Consumer Health division calls on FDA to consider expanding indications and use of over-the-counter nicotine replacement therapies to maximize the public health benefit

Second EU MDR Notified Body Designated In France

Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.

Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103723

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel